Literature DB >> 15172946

Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses.

Vaughan J Carr1, Terry J Lewin, Amanda L Neil, Sean A Halpin, Scott Holmes.   

Abstract

BACKGROUND: Predictors of the costs of psychosis have received insufficient research attention, particularly factors associated with indirect costs. AIMS: To identify the predictors of direct mental health care costs and indirect or time-loss costs in psychotic disorders and to discuss their implications for future interventions.
METHOD: Structured interview data from the Low Prevalence Disorders Study (n=980) were used to examine predictors of the costs of psychosis in Australia. Estimates of annual costs per patient were derived from the perspectives of government and society. Hierarchical regressions were used to assess the contributions to costs of premorbid, psychosocial and clinical factors.
RESULTS: Schizophrenia involved greater costs than other psychotic disorders. Non-completion of high-school education and chronicity of illness course were predictive of higher costs across all categories, and some factors were linked primarily with mental health care costs (e.g. age at onset, current symptomatology) or indirect costs (e.g. male gender, overall disability).
CONCLUSIONS: Several concurrent strategies were recommended, including early intervention programmes and assertive evidence-based rehabilitation and supported employment programmes aimed at reducing disability. The cost-effectiveness of these approaches needs to be evaluated from the perspectives of both government and society.

Entities:  

Mesh:

Year:  2004        PMID: 15172946     DOI: 10.1192/bjp.184.6.517

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  10 in total

1.  A comparative analysis of disability in individuals with bipolar affective disorder and schizophrenia in a sub-Saharan African mental health hospital: towards evidence-guided rehabilitation intervention.

Authors:  Dapo Adebowale Adegbaju; Andrew Toyin Olagunju; Richard Uwakwe
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-02-06       Impact factor: 4.328

2.  The impact of nonclinical factors on care use for patients with depression: a STAR*D report.

Authors:  T Michael Kashner; Madhukar H Trivedi; Annie Wicker; Maurizio Fava; Stephen R Wisniewski; A John Rush
Journal:  CNS Neurosci Ther       Date:  2009-08-27       Impact factor: 5.243

3.  Psychosocial disabilities in patients with schizophrenia.

Authors:  Ma Goreishizadeh; A Mohagheghi; S Farhang; L Alizadeh
Journal:  Iran J Public Health       Date:  2012-05-31       Impact factor: 1.429

4.  Diagnostic change 10 years after a first episode of psychosis.

Authors:  M Heslin; B Lomas; J M Lappin; K Donoghue; U Reininghaus; A Onyejiaka; T Croudace; P B Jones; R M Murray; P Fearon; P Dazzan; C Morgan; G A Doody
Journal:  Psychol Med       Date:  2015-05-04       Impact factor: 7.723

5.  Disability among Attendees with Schizophrenia in a Nigerian Hospital: Further Evidence for Integrated Rehabilitative Treatment Designs.

Authors:  Andrew Toyin Olagunju; Dapo Adebowale Adegbaju; Richard Uwakwe
Journal:  Ment Illn       Date:  2016-12-21

6.  Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.

Authors:  Dominic Pilon; Kruti Joshi; Neeta Tandon; Marie-Hélène Lafeuille; Rhiannon L Kamstra; Bruno Emond; Patrick Lefebvre
Journal:  Patient Prefer Adherence       Date:  2017-03-23       Impact factor: 2.711

7.  Costs of treating patients with schizophrenia who have illness-related crisis events.

Authors:  Baojin Zhu; Haya Ascher-Svanum; Douglas E Faries; Xiaomei Peng; David Salkever; Eric P Slade
Journal:  BMC Psychiatry       Date:  2008-08-26       Impact factor: 3.630

8.  Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up.

Authors:  Tim Ziermans; Sanne de Wit; Patricia Schothorst; Mirjam Sprong; Herman van Engeland; René Kahn; Sarah Durston
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

9.  Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.

Authors:  Michele Wilson; Benjamin Gutierrez; Steve J Offord; Christopher M Blanchette; Anna Eramo; Stephanie Earnshaw; Siddhesh A Kamat
Journal:  Drugs Context       Date:  2016-03-11

10.  Resource allocation for psychosis in Australia.

Authors:  Vaughan J Carr; Amanda L Neil; Terry J Lewin
Journal:  Int Psychiatry       Date:  2004-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.